Apr 25, 2022 6:45 am EDT Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022
Mar 21, 2022 6:45 am EDT Kiora Pharmaceuticals to Participate in Maxim Group's 2022 Virtual Growth Conference March 28th - 30th
Mar 18, 2022 6:45 am EDT Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)
Feb 8, 2022 6:45 am EST Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference
Feb 1, 2022 6:45 am EST Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
Jan 5, 2022 7:00 am EST Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference
Dec 15, 2021 7:00 am EST Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors
Dec 14, 2021 7:15 am EST Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
Nov 15, 2021 7:30 am EST Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update